References
• Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsalate): an endoscopic study: S. Roth, et al.; Semin. Arth. Rheum. 19, 11 (1990)|●Inhibition of NF-kappa B by sodium salicylate and aspirin: E. Kopp & S. Ghosh; Science 265, 956 (1994)|●Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration: J.W. Pierce, et al.; J. Immunol. 156, 3961 (1996)|●The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta: M.J. Yin, et al.; Nature 396, 77 (1998)|●Salsalate improves glycemia and inflammatory parameters in obese young adults: A. Fleischman, et al.; Diabetes Care 31, 289 (2008)|●Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes: A.B. Goldfine, et al.; Clin. Transl. Sci. 1, 36 (2008)|●The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study: J. Koska, et al.; Diabetologia 52, 385 (2009)|●Nuclear factor-kappaB activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans: G.L. Pierce, et al.; Circulation 119, 1284 (2009)|●The effects of salsalate on glycemic control in patients with type 2 diabetes: A randomized trial: A.B. Goldfine, et al.; Ann. Intern. Med. 152, 346 (2010)|●Potential role of salicylates in type 2 diabetes: M.M. Rumore & K.S. Kim; Ann. Pharmacother. 44, 1207 (2010) (Review)|●Effects of salsalate therapy on recovery from vascular injury in female Zucker fatty rats: S.N. Murthy, et al.; Diabetes 59, 3240 (2010)|●Stimulation of human whole-body energy expenditure by salsalate is fueled by higher lipid oxidation under fasting conditions and by higher oxidative glucose disposal under insulin-stimulated conditions: R.C. Meex, et al.; J. Clin. Endocrinol. Metab. 96, 1415 (2011)|●Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans: W. Chai, et al.; Diabetes Care 34, 1634 (2011)|●Modeling diabetes disease progression and salsalate intervention in Goto-Kakizaki rats: Y. Cao, et al.; J. Pharmacol. Exp. Ther. 339, 896 (2011)|●Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes: E. Faghihimani, et al.; Acta Diabetol. (Epub ahead of print) (2011)|●Salicylate downregulates 11beta-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization: M. Nixon, et al.; Diabetes 61, 790 (2012)|●The ancient drug salicylate directly activates AMP-activated protein kinase: S.A. Hawley, et al.; Science 336, 918 (2012)|●Salsalate reduces insulin resistance and plasma glucose level in persons with prediabetes: E. Faghihimani, et al.; Endocr. Pract. (Epub ahead of print) (2012)|●USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
